Easterly Asset Management Hires Peter McCarthy as SVP of Institutional Sales
BEVERLY, Mass.–(BUSINESS WIRE)–Easterly Asset Management (“Easterly”), a multi-affiliate asset manager of high-performing boutique investment firms,…
Year: 2022
Gloat Announces ‘Opportunity Hub’ Powered by Open Ecosystem of Industry-Leading Partners to Help Enterprises Build Best-In-Class Employee Experience Programs
Talent marketplace company Gloat leverages open platform architecture to connect learning, coaching, volunteering, and employee…
OneWeb Partners With Axiros For Management Of Critical Customer Infrastructure
Because reliability in space needs to be matched by reliability on the ground 17 March…
Organogenesis Named One of 50 Highest Growth Companies in Massachusetts by the Boston Business Journal
CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update
Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming…
Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism
Top-line safety and efficacy data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022…
CorMedix Inc. Announces the Appointment of Chief Executive Officer
Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy,…
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea
Published Phase 2 clinical data show DFD-29 had approximately double the efficacy compared to Doxycycline…
Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease Week (DDW2022)
Poster presentations to feature research on leveraging artificial intelligence and machine learning methods to decode…
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that…
Ring Therapeutics Announces the Appointment of Industry Leaders to its Board of Directors
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Ring Therapeutics, a life sciences company founded…
TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures
New collaboration to study the use of Thin Film Freezing technology to formulate dry powder…
Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree
-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™ -$100 million in gross…
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing…
Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging
Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals’…
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3…
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., March 17,…
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical…
Clearmind Medicine Announces Positive Results on CMND-100 trials
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in…